Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is poised for strong growth in the second half of 2026 with expected FDA approvals, new products, and positive clinical trial data. Despite potential negative impacts and external factors, analysts have raised the price target and maintain a Buy rating. The company's focus on oncology and plans to separate its Orthopaedics business, along with a commitment to sustainability and innovative treatments, showcase their dedication to maintaining market share and driving growth in key therapeutic areas.

Bears say

Johnson & Johnson is facing several challenges in their pharmaceutical division, including LOE for key drugs, uncertain uptake of pipeline products, and concerns around drug pricing. Additionally, while their MedTech division has potential for growth, there are hurdles in achieving this, such as the success of their surgical robotics and potential M&A challenges. Furthermore, ongoing litigations, including talc lawsuits, could disrupt business operations.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $267.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $267.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.